• ATI-450 –  pancreatic cancer.
• darolutamide – metastatic hormone sensitive prostate cancer.
• mirvetuximab soravtansine – in ovarian cancer.
• KB-0742 – in MYC-amplified solid tumors.
• zandelisib – in relapsed/refractory follicular lymphoma.
• OP-1250 – in ≥4-line ER+/HER2-negative breast cancer.